Cerebral metabolic response to passive audiovisual stimulation in patients with Alzheimer's disease and healthy volunteers assessed by PET

Journal of Nuclear Medicine

Volumn 41, Issue 4, 2000, Pages 575-583

  Pietrini, Pietro ^a   Alexander, Gene E ^b   Furey, Maura L ^b   Dani, Alessio ^b   Mentis, Marc J ^b   Horwitz, Barry ^b   Guazzelli, Mario ^b   Schapiro, Mark B ^b   Rapoport, Stanley I ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NONE

Author keywords

Activation; Brain; Cognition; Dementia; FDG; PET

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUDITORY STIMULATION; BASAL METABOLIC RATE; BRAIN METABOLISM; CELL VIABILITY; CLINICAL ARTICLE; COGNITION; COMPLIANCE (PHYSICAL); DEMENTIA; ENERGY CONSUMPTION; FEMALE; HUMAN; MALE; NEUROTRANSMITTER RELEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; VISUAL STIMULATION;

ACOUSTIC STIMULATION; AGED; ALZHEIMER DISEASE; BRAIN; CASE-CONTROL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; PHOTIC STIMULATION; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034071698     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Yarowsky PJ, Ingvar DH. Neuronal activity and energy metabolism. Fed Proc. 1981;40:2353-2362.
2. Sokoloff L. Relationship between functional activity and energy metabolism in the nervous system: whether, where and why. In: Lassen NA, Ingvar DH, Raichle ME, Friberg L. eds. Brain Work and Mental Activity: Quantitative Studies with Radioactive Tracers - Alfred Benzon Symposium VIII. Vol 31. Copenhagen, Denmark: Munksgaard; 1991:52-67.
3. Phelps ME, Huang SC, Hoffman EJ, Selin MS, Sokoloff L, Kuhl DE. Tomographic measurement of local glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
4. Herscovitch P, Markham J, Raichle ME. Brain blood flow measured with intravenous O-15 water: part 1. Theory and error analysis. J Nucl Med. 1983;24:782-789.
5. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cereb Blood Flow Metab. 1985;5:193-200.
6. Kumar A, Schapiro MB, Grady C, et al. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology. 1991;4:35-46.
7. Lewis DA, Campbell MJ, Terry RD, Morrison JH. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices. J Neurosci. 1987;7:1799-1808.
8. DeCarli CS, Atack JR, Ball MJ, et al. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration. 1992;1:113-121.
9. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572-580.
10. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457-464.
11. Hatanpää K, Brady DR, Stoll J, Rapoport SI, Chandrasekaran K. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1996;40:411-420.
12. Grady CL, Haxby JV, Horwitz B, et al. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiol Aging. 1993;14:35-44.
13. Rapoport SI, Grady CL. Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer disease. Int J Neurosci. 1993;70:39-56.
14. Duara R, Barker WW, Chang J, Yoshii F, Loewenstein DA, Pascal S. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J Cereb Blood Flow Metab. 1992;12:927-934.
15. Kessler J, Herholz K, Grond M, Heiss WD. Impaired metabolic activation in Alzheimer's disease: a PET study during continuous visual recognition. Neuropsychologia. 1991;29:229-243.
16. Mentis MJ, Horwitz B, Grady CL, et al. Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded stress test during PET. Am J Psychiatry. 1996;153:32-40.
17. Mentis MJ, Alexander GE, Krasuski J, et al. Increasing neural response required to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am J Psychiatry. 1998;155:785-794.
18. Pietrini P, Ricciardi E, Furey ML, et al. Effects of the healthy aging process on the relation of regional cerebral blood flow (rCBF) to glucose metabolism (rCMRglc) during rest and audiovisual stimulation in humans [abstract]. J Neurosci. 1999;25:1144.
19. Pietrini P, Dani A, Furey ML. et al. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Am J Psychiatry. 1997;154:1063-1069.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology. 1984;34:939-944.
21. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897-916.
22. Brooks RA, Di Chiro G, Zukerberg BW, Bairamian D, Larson SM. Test-retest studies of cerebral glucose metabolism using fluorine-18 deoxyglucose: validation of method. J Nucl Med. 1987;28:53-59.
23. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellack L, Karasu TB, eds. Geriatric Psychiatry: A Handbook for Psychiatrists and Primary Care Physicians. New York, NY: Grune and Stratton; 1976:77-121.
24. Pietrini P, Azari NP, Grady CL, et al. Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: A longitudinal evaluation. Dementia. 1993;4:94-101.
25. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942-947.
26. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758.
27. Ibáñez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 1998;50:1585-1593.
28. Hatanpää K, Isaacs KR, Shirao T, Brady DR, Rapoport SI. Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:637-643.
29. Chandrasekaran K, Hatanpää K, Brady DR, Rapoport SI. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Exp Neurol. 1996;142:80-88.
30. Seitz RJ, Roland PE. Vibratory stimulation increases and decreases the regional cerebral blood flow and oxidative metabolism: a positron emission tomography (PET) study. Acta Neurol Scand. 1992;86:60-67.
31. Haxby JV, Horwitz B, Ungerleider LG, Maisog JM, Pietrini P, Grady CL. The functional organization of human extrastriate cortex: a PET-rCBF study of selective attention to faces and locations. J Neurosci. 1994;14:6336-6353.
32. Kawashima R, O'Sullivan BT, Roland PE. Positron emission tomography studies of cross-modality inhibition in selective attentional tasks: closing the "mind's eye." Proc Natl Acad Sci USA. 1995;92:5969-5972.
33. Morrison JH, Hof PR, Campbell MJ, et al. Cellular pathology in Alzheimer's disease: implications for corticocortical disconnection and differential vulnerability. In: Rapoport SI, Petit H, Leys D, Christen Y, eds. Imaging, Cerebral Topographv and Alzheimer's Disease: Research and Perspectives in Alzheimer's Disease. Berlin, Germany: Fondation Ipsen, Springer-Verlag; 1990:19-40.
34. Azari NP, Rapoport SI, Grady CL, et al. Patterns of interregional correlations of cerebral glucose metabolic rates in patients with dementia of the Alzheimer type. Neurodegeneration. 1992;1:101-111.
35. Whitehouse PJ. Neurotransmitter receptor alterations in Alzheimer's disease: a review. Alzheimer Dis Assoc Disorders. 1987;1:9-18.
36. Flynn DD, Weinstein DA, Mash DC. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol. 1991;29:256-262.
37. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs. 1997;53:762-768.
38. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.